(Q51553332)

7 April 2018

title

Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients. (English)

1 reference

7 April 2018

1 reference

2

1 reference

7 April 2018

author name string

Rustin D Crutchley

1

1 reference

7 April 2018

Adel Sulaiman

3

1 reference

7 April 2018

Jill Hochreitter

4

1 reference

7 April 2018

Gene D Morse

5

1 reference

7 April 2018

publication date

22 November 2010

1 reference

7 April 2018

Journal of Pharmacy Practice

published in

1 reference

7 April 2018

volume

24

1 reference

7 April 2018

issue

2

1 reference

7 April 2018

page(s)

216-222

1 reference

7 April 2018

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Predictors of virological response to atazanavir in protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010380923

21 January 2018

Identifiers

DOI

10.1177/0897190010380923

1 reference

7 April 2018

1 reference

7 April 2018